[Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients].
We analysed patients with focal epilepsies treated with zonisamide (ZNS) as add-on treatment to topiramate (TPM) and other antiepileptic drugs (mean 2). Twenty-five patients were evaluated, and follow-up data were available in 19 (12 women, seven men, mean age 34 years). The mean time until first follow-up investigation was 17 weeks. At that point in time the mean ZNS dosage was 344 mg and mean TPM dosage was 398 mg. Eight patients (42%) achieved seizure frequency reduced by at least 50%. Six patients (31%) reported side effects, especially cognitive impairment and weight loss (>5 kg) in two patients. In the further course of treatment, ZNS was discontinued in two of three patients because of cognitive impairment. We conclude that add-on treatment including ZNS and TPM can not be recommended for chronic treatment of epilepsy.
Bös
M
M
Klinik für Epileptologie, Universitätskliniken Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany. monika.boes@ukb.uni-bonn.de
Bauer
J
J
D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage*; D002648:Child; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000077236:Topiramate; D016896:Treatment Outcome; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000077236:Topiramate; D005632:Fructose; D000078305:Zonisamide